Castleman Disease (Unicentric)

Comprehensive Clinical Guide: Unicentric Castleman Disease (UCD)

1. Introduction and Clinical Overview

Unicentric Castleman Disease (UCD) is a rare, non-malignant, lymphoproliferative disorder characterized by the enlargement of a single lymph node or a single region of lymph nodes. Unlike Multicentric Castleman Disease (MCD), which involves systemic inflammatory symptoms and multi-organ involvement, UCD is typically localized and often asymptomatic.

Historically termed "giant lymph node hyperplasia" or "angiofollicular lymph node hyperplasia," UCD represents a distinct clinical entity within the spectrum of Castleman-related disorders. While it is categorized as a lymphoproliferative disorder, it is currently classified by the WHO as a benign condition, though it carries a risk of transformation or localized recurrence if not surgically addressed. The hallmark of UCD is the localized nature of the disease, which allows for curative resection in the vast majority of cases.

2. Etiology and Pathophysiology

The etiology of UCD remains largely idiopathic, though current research suggests an interplay between localized immune dysregulation and cellular proliferation.

Key Mechanisms

• Lymphoid Hyperplasia: The primary driver is the uncontrolled proliferation of lymphoid tissue within a single node or chain.
• Cytokine Dysregulation: While systemic cytokines (like IL-6) are rampant in MCD, in UCD, cytokine production is generally localized to the affected node.
• Angiogenesis: The "angiofollicular" nature of the disease is driven by increased vascular endothelial growth factor (VEGF) expression within the affected node, resulting in prominent capillary proliferation.
• Genetic Factors: Unlike MCD, which is frequently associated with HHV-8 (Human Herpesvirus 8) in HIV-positive individuals, UCD is almost exclusively HHV-8 negative.

Histopathological Subtypes

UCD is classified into three distinct histological variants based on morphological findings:

3. Clinical Presentation and Staging

Standard Presentation

Patients with UCD are often asymptomatic, with the disease discovered incidentally during routine imaging (e.g., chest X-ray or CT scan). When symptoms do occur, they are typically compressive in nature due to the physical mass effect of the enlarged node.

• Mass Effect: Depending on location (mediastinal, cervical, retroperitoneal), patients may experience dyspnea, dysphagia, or localized pain.
• Constitutional Symptoms: Rare in UCD. If systemic symptoms (fever, night sweats, weight loss) are present, the diagnosis must be re-evaluated to rule out MCD or malignancy.

Clinical Staging

UCD does not follow a formal "staging" system like lymphoma (e.g., Ann Arbor). Instead, clinicians utilize the Castleman Disease Collaborative Network (CDCN) criteria to differentiate UCD from MCD, as the treatment paradigms differ significantly.

4. Diagnostic Workup and Differential Diagnosis

Diagnosis of UCD is primarily histopathological. Imaging provides the roadmap, but biopsy provides the confirmation.

Key Diagnostic Tests

1. Excisional Biopsy: The gold standard. Needle core biopsies are often insufficient due to the need to assess the architecture of the entire node.
2. Imaging:
   • CT/MRI: Essential for locating the mass and evaluating vascular supply (UCD nodes are often hypervascular).
   • PET-CT: Useful to confirm that the disease is truly unicentric.
3. Laboratory Studies:
   • CBC: Generally normal in UCD.
   • Inflammatory Markers (CRP/ESR): Usually normal; elevation should trigger a suspicion for MCD.
   • HHV-8 Testing: Essential to rule out HHV-8-associated MCD.

Differential Diagnosis

It is critical to distinguish UCD from conditions that mimic lymphadenopathy:
* Lymphoma (Hodgkin and Non-Hodgkin): Often requires IHC markers (CD20, CD3, CD30, etc.) to rule out.
* Metastatic Carcinoma: Always rule out a primary tumor source.
* Tuberculosis/Fungal Infections: Chronic granulomatous disease can mimic the morphology.
* IgG4-Related Disease: Can present with similar lymphadenopathy; serum IgG4 levels should be measured.

5. Management and Prognosis

Standard of Care

The definitive treatment for UCD is complete surgical resection.

• Surgical Excision: In the majority of cases, total removal of the affected node(s) is curative.
• Pre-operative Embolization: Due to the high vascularity of HV-type UCD, pre-operative embolization is sometimes performed to reduce intraoperative hemorrhage risk.
• Radiation Therapy: Reserved for cases where the mass is unresectable or in surgically high-risk locations (e.g., near major vascular structures).

Long-term Prognosis

The prognosis for UCD is excellent. Following complete surgical excision, the 5-year survival rate approaches 100%. Recurrence is rare, though long-term follow-up (annual imaging for 3-5 years) is recommended to ensure no new lymphadenopathy develops.

6. Risks and Contraindications

• Surgical Risk: The primary risk factor involves the anatomical proximity of the UCD mass to vital structures (e.g., the aorta or carotid arteries).
• Misdiagnosis Risk: The greatest danger in UCD management is misdiagnosing it as a malignancy and performing overly aggressive chemotherapy, or conversely, misdiagnosing an aggressive lymphoma as benign UCD.
• Contraindications: There are no specific contraindications to surgery other than standard surgical risk assessments. Pharmacological agents (like IL-6 inhibitors) are generally contraindicated in UCD as they are indicated for MCD and are unnecessary for localized disease.

7. Frequently Asked Questions (FAQ)

1. Is Unicentric Castleman Disease a form of cancer?
No. UCD is classified as a non-malignant lymphoproliferative disorder. It does not metastasize like cancer.

2. Is UCD contagious?
No. There is no evidence that UCD is contagious or caused by an infectious pathogen in the way that viral illnesses are.

3. What is the difference between UCD and MCD?
UCD is localized to one node or region and is usually cured by surgery. MCD is systemic, involves multiple lymph node groups, and requires systemic medical therapy (immunomodulators).

4. How is the diagnosis confirmed?
Diagnosis is confirmed through an excisional lymph node biopsy interpreted by a pathologist specializing in hematopathology.

5. Does UCD cause symptoms like fever or weight loss?
Rarely. If a patient experiences significant systemic symptoms, they should be re-evaluated to confirm the diagnosis is not actually Multicentric Castleman Disease.

6. Is surgery always required?
Yes, surgery is the standard of care. Because UCD is a localized mass, removing it removes the disease.

7. Can UCD recur after surgery?
Recurrence is very rare if the surgeon achieves a complete resection (R0 resection).

8. What role do IL-6 inhibitors (like siltuximab) play in UCD?
Siltuximab is approved for MCD. It is generally not used for UCD because surgery is sufficient and curative.

9. Are there genetic tests for UCD?
Currently, there is no specific genetic test for UCD. Diagnosis relies on histological markers and the exclusion of other diseases.

10. What imaging is best for follow-up?
CT scans with contrast are the standard for monitoring the site of the original resection during the post-operative surveillance period.

8. Clinical Summary Table

9. Conclusion

Unicentric Castleman Disease represents a unique intersection of surgical pathology and clinical management. While it is a "benign" condition, its potential for local mass effect and the necessity for precise differential diagnosis—to distinguish it from malignant lymphomas—mandate a rigorous, multidisciplinary approach. With early surgical intervention and accurate histopathological assessment, the clinical outlook for patients with UCD remains overwhelmingly positive, marking it as a condition where definitive surgical action is the cornerstone of patient care.

Disclaimer: This document is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.